Tagamet

(Cimetidine)

PreclinicalSmall molecule

DDT MedTech, LLC

Tagamet is one of 82 small molecule programs targeting Pneumonia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

PneumoniaActive, not recruiting

HIV InfectionActive, not recruiting

PneumoniaPreclinical

Active, not recruiting

HIV InfectionPreclinical

Active, not recruiting

Competition

Competitive Landscape

155 competitors in Pneumonia

#DrugCompanyPhaseTrials

Primaquine

Sanofi

Preclinical

1 2

Retrovir

BBp Consulting, Inc

Preclinical

2 3

Primsol

CConrado Roberto Hoffmann Filho

Preclinical

2 4

Protonix

WWyeth-Lederle Vaccines

Preclinical

1 5

Alka-Seltzer

AAbbott

Preclinical

1 6

Tylenol

KKenvue Brands

Preclinical

1 7

Salbutamol

GSK

Preclinical

1 8

Foscavir

CClinigen, Inc.

Preclinical

—9

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—10

Angiotensin-Converting Enzyme Inhibitors

Boehringer Ingelheim

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Post-ApprovalRecruiting

Excretion

NCT06056583

Clinical

Trials by Indication[1]

Interaction2 trials

Drug-drug Interaction Study of Gepotidacin

Completed· GSK logo

GSK·Phase 1·NCT04493931·64 enrolled

Pharmacokinetic Drug-Drug Interaction Study to Identify Biomarkers of Kidney Transporters

Completed·WWashington State University·Phase 1·NCT05365451·16 enrolled

HIV infection1 trial

A Study to Evaluate the Effect of Cimetidine on CD4 Lymphocyte Counts in HIV Infection

Completed·CCommunity Research Initiative of New England·N/A·NCT00002092

AIN1 trial

This Study Tests the Effect of Certain Medicines on the Transport of Other Medicines in the Body of Healthy Men

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT03307252·45 enrolled

Serous Carcinoma1 trial

Papillary Serous Carcinoma of the Endometrium

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00515073·30 enrolled

Biological Therapy1 trial

Biological Therapy in Treating Patients With Metastatic Cancer

Completed·HHoag Memorial Hospital Presbyterian·Phase 2·NCT00002733·30 enrolled

10 more indications

Breast Cancer1 trial

Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel

Completed·OOhio State University Comprehensive Cancer Center·Phase 2/3·NCT04862585·130 enrolled

TED1 trial

Effect of Repeated Doses of BI 1060469 and BI 1021958 on Glomerular Filtration Rate (GFR) in Healthy Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02202512·53 enrolled

Pneumonia1 trial

Proton Pump Inhibitors and Risk of Community-acquired Pneumonia

Completed·CCanadian Network for Observational Drug Effect Studies, CNODES··NCT02555852·4,238,504 enrolled

Peptic ulcer1 trial

High Dose Esomeprazole Na for Prevention of Rebleeding After Successful Endoscopic Therapy of a Bleeding Peptic Ulcer

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT01757275·239 enrolled

Atopic Dermatitis1 trial

The Efficacy of Cimetidin for Acute - Extrinsic Atopic Dermatitis Treated With Standard Therapy

Unknown status·FFakultas Kedokteran Universitas Indonesia·Phase 3·NCT04018131·26 enrolled

Intravenous1 trial

Stress Ulcer Prophylaxis of Intravenous Esomeprazole in Chinese Seriously Ill Patients

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT02157376·343 enrolled

Tics1 trial

Effect of Cimetidine on the Pharmacokinetics of Lucerastat in Healthy Subjects

Completed· Idorsia Pharmaceuticals Ltd. logo

Idorsia Pharmaceuticals Ltd.·Phase 1·NCT03380455·14 enrolled

Excretion1 trial

Drug Excretion in Breast Milk

Recruiting·UUniversity of Washington·Phase 4·NCT06056583·50 enrolled

Erythropoietic Protoporphyria1 trial

Effect of Oral Cimetidine in the Protoporphyrias

Completed·AAmy K. Dickey, M.D.·Phase 2·NCT05020184·26 enrolled

Unspecified3 trials

Evaluating The Effects Of Cimetidine On The Elimination Of PD 0332334 From The Body

Terminated· Pfizer logo

Pfizer·Phase 1·NCT00800280·12 enrolled

Effect of Cimetidine on the PK of Imeglimin

Completed·PPoxel SA·Phase 1·NCT03618316·16 enrolled

Class 3 Biowaivers

Completed·UUniversity of Maryland, Baltimore·Phase 1·NCT01010698·48 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

TAGAMET

NDA NDA017939

Jan 1, 1982

TAGAMET

NDA NDA017924

Jan 1, 1982

TAGAMET

NDA NDA017920

Oct 31, 1985

TAGAMET HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

NDA NDA019434

Jun 19, 1995

TAGAMET HB

NDA NDA020238

Jul 9, 1999

TAGAMET HB 200

NDA NDA020951

Sources

References

[1]
ClinicalTrials.gov — 18 trial records for Cimetidine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cimetidine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cimetidine. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA020951). U.S. Food & Drug Administration.
[5]
SEC EDGAR — DT MedTech, LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: DDT MedTech, LLC

Tagamet

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Interaction2 trials

HIV infection1 trial

AIN1 trial

Serous Carcinoma1 trial

Biological Therapy1 trial

Breast Cancer1 trial

TED1 trial

Pneumonia1 trial

Peptic ulcer1 trial

Atopic Dermatitis1 trial

Intravenous1 trial

Tics1 trial

Excretion1 trial

Erythropoietic Protoporphyria1 trial

Unspecified3 trials

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News